Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.
Trends Cardiovasc Med. 2022 Nov;32(8):501-510. doi: 10.1016/j.tcm.2021.10.001. Epub 2021 Oct 5.
Atrial fibrillation (AF) is the commonest sustained cardiac rhythm disorder associated with an increased risk of stroke and systemic embolic events. The prevention of stroke using oral anticoagulants has been a pivotal component of AF management. The purpose of this review is to summarize recent advances in the treatment and prevention of stroke in AF over the last 5 years. We performed a comprehensive structured literature search using MEDLINE for publications from 11 March 2015 through to 31 December 2020. We focused mainly on primarily published research articles and systematic reviews including updates in different international guidelines. We found that improved awareness and detection of AF and use of clinical risk stratification are central to the identification of patients at risk of stroke who would benefit from oral anticoagulation. The recommendation of non-vitamin K antagonist oral anticoagulants over warfarin in both efficacy and safety perspective is represented in all international guidelines. Beyond stroke prevention, there is a move to more holistic or integrated care management of AF, which has been shown to improve outcomes. We conclude that stroke prevention remains a dominant part of the management of patients with AF. Not all stroke risk factors carry equal weight, and many require additional scrutiny (e.g. severity of CAD, type of diabetes, duration of hypertension). The utilization of clinical risk scores to help decision-making should take into account that these scores are mere simplification tools to aid decision-making and the additional clinical benefit with more complex risk scores and addition of biomarkers is limited. Also, stroke and bleeding risks are dynamic and require regular review. Instead of arbitrarily categorizing patients into (artificial) low, moderate, and high stroke risk strata, anticoagulation should be offered to all patients with AF unless they are low risk with no risk factors for stroke. Stroke prevention is also part of the proactive, integrated care approach to holistic management of patients with AF, which can be simplified in the ABC (Atrial fibrillation Better Care) pathway: 'A' Avoid stroke/Anticoagulation; 'B' Better symptom management emphasising patient-centred symptom directed decisions on rate or rhythm control strategies; and 'C' refers to Cardiovascular risk and comorbidity optimization, including lifestyle changes and attention to patient values and preferences, as well as the psychological morbidity associated with AF.
心房颤动(AF)是最常见的持续性心律失常,与中风和全身性栓塞事件的风险增加有关。使用口服抗凝剂预防中风一直是 AF 管理的关键组成部分。本综述的目的是总结过去 5 年 AF 中风治疗和预防方面的最新进展。我们使用 MEDLINE 进行了全面的结构化文献检索,检索时间为 2015 年 3 月 11 日至 2020 年 12 月 31 日。我们主要关注主要发表的研究文章和系统评价,包括不同国际指南的更新。我们发现,提高对 AF 的认识和检测,以及使用临床风险分层,是确定有中风风险、受益于口服抗凝治疗的患者的核心。所有国际指南都建议在疗效和安全性方面使用非维生素 K 拮抗剂口服抗凝剂而不是华法林。除了预防中风,还有一种向更全面或综合的 AF 护理管理转变的趋势,这已被证明可以改善结果。我们的结论是,中风预防仍然是 AF 患者管理的主要部分。并非所有中风危险因素都同等重要,许多危险因素需要进一步审查(例如,CAD 严重程度、糖尿病类型、高血压持续时间)。利用临床风险评分来帮助决策时,应考虑到这些评分只是帮助决策的简化工具,更复杂的风险评分和添加生物标志物的额外临床益处是有限的。此外,中风和出血风险是动态的,需要定期审查。不应该将患者任意分为(人为的)低、中、高中风风险层,除非患者风险低且没有中风危险因素,否则应向所有 AF 患者提供抗凝治疗。中风预防也是对 AF 患者进行积极、综合护理管理的一部分,这可以在 ABC(心房颤动更好的护理)途径中简化:'A'预防中风/抗凝;'B'更好的症状管理,强调以患者为中心的症状决定,选择节律或心率控制策略;'C'指心血管风险和合并症的优化,包括生活方式的改变和对患者价值观和偏好的关注,以及与 AF 相关的心理发病率。